BIND Therapeutics, Inc. BIND today reported data demonstrating the efficacy and
tolerability of BIND's Accurin platform with multiple anti-cancer
agents. These data, which were presented at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics
held in Boston, November 5-9, 2015, describe the ability of Accurins to
control the biodistribution of therapeutic payloads across multiple
active anti-cancer agents, pathways and targets, which results in either
improved efficacy, tolerability or both.
The four posters presented include preclinical and clinical
pharmacokinetic data from BIND's clinical stage Accurin compound,
BIND-014; data from BIND's preclinical stage Accurin, BIND-510; and new
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in